Research and development

Global innovative bio technology company leading the development of gene-cell therapy


  • Validity

    Regenerate blood vessel and also re-construct damaged cephalin with complex functions promoting the generation and differentiation of nerve cells
  • Safety

    Formation to be injected in the operation room in generic class as the final formation is in the form of cells by minimizing the risk from introgressed genes by using 3rd generation lentivirus
  • Productivity

    Convenient for commercialization with possible mass production of cells with consistent features of integrated genes
  • Business

    Convenient delivery as an off-the-shelf that cells with consistent and high quality can be provided
    the research for clinical phase 3 performed by many institutions. Therefore, it is possible to increase the success rate of clinical
    phase 3 test.